Company Announcement

2019/05/16
Johnson & Johnson Outlines Strategy to Deliver Above-Market Growth at 2019 Pharmaceutical Business Review
Highlights progress and commitment to deliver breakthrough medicines to meet the needs of patients around the world Plans to maximize potential of lea...
2017/09/08
[Media Report] Serving In the Name of Progress
In an interview with China Daily, Joaquin Duato, Executive Vice-President and Worldwide Chairman of Pharmaceuticals at Johnson&Johnson
2017/08/30
China Food and Drug Administration approves IMBRUVICA? (ibrutinib) for the treatment of two forms of blood cancer with high unmet treatment needs
[Beijing], [30 August, 2017] – Xian Janssen Pharmaceutical Ltd.
2017/08/05
Enlightened Light, Blooming Bright -- 14th Johnson & Johnson China World Window on Pediatrics Seminar Draws to a Successful Conclusion
The 14th?Johnson & Johnson China World Window on Pediatrics Seminar, co-hosted by Shanghai Johnson & Johnson Pharmaceuticals Ltd. and Xian Jan...
2016/01/08
ZYTIGA? - New prostate cancer treatment now available to patients across China
January 8, 2016, Beijing – Today, Xian Janssen Pharmaceutical Ltd., announced the launch of ZYTIGA? (abiraterone acetate), a new kind of treatment for...
2015/10/13
Xian Janssen Celebrates 30 Years of Commitment to China
Xi’an, China, 13 October 2015 – Xian-Janssen reaffirmed its commitment to partner with the Chinese Government and invest in healthcare innovation in C...